Guidance on novel influenza A/H1N1 in solid organ transplant recipients.
Novel influenza A/H1N1 virus has caused significant illness worldwide. In response to this global crisis, the American Society of Transplantation (AST) Infectious Diseases Community of Practice and the Transplant Infectious Diseases section of The Transplantation Society (TTS) developed a guidance document for novel H1N1. In this paper, we discuss current guidance for H1N1 as it relates to solid organ transplantation. We include discussion around clinical presentation, diagnosis, therapy and prevention specifically addressing areas such as chemoprophylaxis, immunization and donor-derived infection. Although this document addresses conditions specific to novel H1N1, many principles could be applied to future pandemics. As new information emerges about novel H1N1, updates will be made to the electronic version of the document posted on the websites of the AST and TTS.
Kumar
D
D
Transplant Infectious Diseases, University of Alberta, Edmonton, Alberta, Canada. kumar@ualberta.ca
Morris
M I
MI
Kotton
C N
CN
Fischer
S A
SA
Michaels
M G
MG
Allen
U
U
Blumberg
E A
EA
Green
M
M
Humar
A
A
Ison
M G
MG
D000998:Antiviral Agents / Q000627:therapeutic use; D002648:Child; D002675:Child, Preschool; D000075202:Contraindications; D006801:Humans; D016867:Immunocompromised Host; D007223:Infant; D053118:Influenza A Virus, H1N1 Subtype; D007252:Influenza Vaccines / Q000008:administration & dosage; D007251:Influenza, Human / Q000175:diagnosis / Q000517:prevention & control / Q000628:therapy / Q000635:transmission; D014019:Tissue Donors; D019737:Transplants; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated / Q000008:administration & dosage
D000998:Antiviral Agents; D007252:Influenza Vaccines; D014613:Vaccines, Attenuated; D015164:Vaccines, Inactivated